Fairchem Organic Q1 FY27 Results (NSE: FAIRCHEMOR)
Signal: Margin expansion
The read
The key inflection is a sharp margin-led recovery: gross margin expanded 417bps YoY to 22.6% and EBITDA margin expanded 621bps to 10.3%, while revenue grew 34.4%; however, the sustainability of the margin gain remains unconfirmed because the filing does not identify the input-cost or mix driver and finance costs rose 82.8%.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹176.15 Cr | +34.4% | +50.6% |
| EBIT | ₹15.47 Cr | +490.5% | |
| Net profit | ₹10.01 Cr | +752.8% | |
| EPS | ₹7.95 | +783.3% | |
| EBIT margin | 10.3% |
P&L walk
Revenue increased to ₹17,614.57 lakh, +34.4% YoY and +50.6% QoQ, while gross margin expanded to 22.6% from 18.5%; EBITDA rose to ₹1,821.46 lakh, +239.9% YoY, and EBITDA margin expanded to 10.3%, with PAT reaching ₹1,001.38 lakh, +752.8% YoY.
Segments
The single Speciality Chemicals segment drove the recovery, with segment revenue rising 34.4% YoY to ₹17,614.57 lakh and segment result increasing 491.3% to ₹1,547.46 lakh; there is no subsidiary or segment diversification to identify.
Key positives
- Revenue rose 34.4% YoY to ₹17,614.57 lakh, while EBITDA grew 239.9% to ₹1,821.46 lakh and EBITDA margin expanded 621bps to 10.3%.
- Operating leverage is evident: EBITDA grew +239.9% versus revenue +34.4%, a +205.5pp gap, while employee costs grew 12.3% and depreciation grew 0.2%.
- Gross margin expanded 417bps YoY to 22.6% as cost of materials consumed fell to 68.3% of revenue from 69.2%.
- EPS increased to ₹7.95 from ₹0.90, supported by PAT growth and the extinguishment of 4,25,000 shares in the buyback.
Key concerns
- Finance costs increased 82.8% YoY to ₹183.79 lakh and 64.1% QoQ, limiting the conversion of operating improvement into bottom-line growth.
- The filing does not disclose volumes, realisations or the reason for the 417bps gross-margin expansion, leaving the durability of the margin inflection unconfirmed.
Research and educational content only. Not investment advice.